Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
Only Adam knows what his business commitments are; whether he will have the time to give to Val or the inclination to become involved beyond being a major shareholder.
What I know is that on the 14th June he said
...'They’ve bought a business that had an equipment asset value of probably 3+ million; a bio bank with significant worth; and all the IP. For 170 grand. Credit where credit is due. This is an excellent bit of business.'
There have also been other very recent and positive comments from him about the company and what they are doing.
Might it be wise to reflect on the comments he has made as It might not be the best business decision to vote the ones off who got the deal and one assumes have the plan to get it up and running. In addition,many other posters were recently saying how good the lab business would be for the company, (admittedly some were rampant rampers though!)
Do we really want a complete change, particularly if Adam was not able or willing to accept a board position for whatever reason.
Sorry about the long post but not long till we know one way or the other.
Well said Porky9,
....'Look, I hope I’m proved wrong about THX but I just don’t see it. I would rather the drug go to a major biotech that can fund trials and give them it for free with a guarantee payment on a milestone if it proves to work.'
The conversation on here is a Deja vu moment for those of us who were here and can remember Dr Dilly's appointment. In my mind at the time, shareholders voted her in without any due diligence at all and as they say, what goes round comes round. Personally I was against her appointment and voiced it on here, but I now think she was faced with an impossible task as they those legacy products were already lingering from previous management, albeit she has tried to move them forward.
Not sure she will survive the vote but for me, if she does, then I think she will be focussing on rebuilding Val into a new business model of lab work, perhaps a good prospect longer term, and if any of the agreements come in then they will be a bonus, but I am certainly not holding my breath on them.
I also think any new CEO would simply let the legacy products wither on the vine with the faint hope they come good . We would then have to go through more turmoil when they introduced new direction to the business.
With all of that in mind I will supporting her as I think she has/is slowly getting things on a even keel and I will be putting my shares in the bottom drawer for a few years and see how the lab business develops.
Good luck to all, not long to wait to see one way or the other.
Not sure I am following your train of thought here as Murphy canyon looks like it had been delisted from 14 April 2023.
MURPHY-CANYON-ACQUISITION-CORP-Notice-of-Delisting-or-Failure-to-Satisfy-a-Continued-Listing-Rule-
'In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company will have 180 calendar days, or until October 9, 2023 (the "Compliance Date"), to regain compliance with the MVLS Rule. To regain compliance with the MVLS Rule, the MVLS for the Class A Common Stock must be at least $50 million for a minimum of 10 consecutive business days at any time during this 180-day period. If the Company regains compliance with the MVLS Rule, Nasdaq will provide the Company with written confirmation and will close the matter.
If the Company does not regain compliance with the MVLS Rule by the Compliance Date, Nasdaq will provide notice that the Class A Common Stock will be subject to delisting. In the event of such notification, the Nasdaq rules permit the Company an opportunity to appeal Nasdaq's determination. The Letter notes that the Company may be eligible to transfer the listing of its securities to the Nasdaq Capital Market (provided that it then satisfies the requirements for continued listing on that market). The Company is monitoring the MVLS of its Class A Common Stock and will consider options available to it to potentially achieve compliance.'
Pm you said, amongst other things.....................'World class new compounds coming through for a quick evaluation in our lab. Each one is worth at least 10p moving into SPV and more overtime so huge potential'
Did I miss this news or is it simply your opinion that is what will happen? I do hope so but my view is that I am not sure many 'world class new compounds' will go through a newly started lab, without a decent reputation that it has built up with perhaps smaller contracts first.
Metom,
Ref the twitter comment you posted, what is your take on this? The comment and picture appears to me to be an update to the 2022 article about the link with Kings.
https://www.kcl.ac.uk/news/drug-treatment-for-triple-negative-breast-cancer
Are you suggesting that they are giving 'a heads up' about some sort of progress with this ?
I think it might be due to the V Formation partner they use having a new intern for two week placement, apparently he is looking after their clients social media, hence the flurry of info. Hopefully he will find and post up some good news in his search.
PI8
'As we start the final week of March and Endometriosis Month, we'd like to take the opportunity to share one of our key therapeutic areas of focus: women's health'.
Nothing definite then and perhaps the tweet might have had more impact if it was sent out during the first week of the Endometriosis Month instead of trying to squeeze it into the last couple of days!
In my mind Porky9 has hit the nail on the head with this sentence,
.......However it’s not a substitute for license deals which was what this entire business was founded on doing. The millions in drug investment and now a switch focus to lab contracts.
I agree with him, as what I perceived many years ago to be a high risk /high potential return is switching to a different business model of high risk but slow and steady return. I still think val will be a good long term investment but we now have to go through the lab building stage to attract the research customers to give us the income while we develop our own products.
I really do hope I am wrong and the markets all jump in and the SP rockets on this news.